Yoshinobu Koyama

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados et al. · The Lancet · 2018 · 359 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +14

Interleukin 1 Activates STAT3/Nuclear Factor-κB Cross-talk via a Unique TRAF6- and p65-dependent Mechanism

Yasuhiro Yoshida, Arvind Kumar, Yoshinobu Koyama et al. · Journal of Biological Chemistry · 2004 · 135 citations · Full text

Life Sciences, Immunology, Molecular Biology +17

Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan

Wataru Fukuda, Tadamasa Hanyu, Masaki Katayama et al. · Annals of the Rheumatic Diseases · 2016 · 93 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

A Novel STAT-Like Factor Mediates Lipopolysaccharide, Interleukin 1 (IL-1), and IL-6 Signaling and Recognizes a Gamma Interferon Activation Site-Like Element in the <i>IL1B</i> Gene

Junichi Tsukada, Wayne R. Waterman, Yoshinobu Koyama et al. · Molecular and Cellular Biology · 1996 · 81 citations · Full text

Life Sciences, Immunology, Molecular Biology +15

Cross-linking of intercellular adhesion molecule 1 (CD54) induces AP-1 activation and IL-1beta transcription

Yoshinobu Koyama, Yoshiya Tanaka, Kazuyoshi Saito et al. · The Journal of Immunology · 1996 · 74 citations · Full text

Life Sciences, Cell Biology, Immunology +13